## Keith K H Wong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/91669/publications.pdf

Version: 2024-02-01

95 papers 3,637 citations

172457 29 h-index 138484 58 g-index

97 all docs 97
docs citations

97 times ranked 3710 citing authors

#	Article	IF	CITATIONS
1	Australian Consultant Pharmacists' Potential Roles in Sleep Health Care: Exploring a New Avenue for Improving the Management of Insomnia. Behavioral Sleep Medicine, 2022, 20, 622-637.	2.1	2
2	Brain mitochondrial dysfunction and driving simulator performance in untreated obstructive sleep apnea. Journal of Sleep Research, 2022, 31, e13482.	3.2	4
3	Improvements in cognitive function and quantitative sleep electroencephalogram in obstructive sleep apnea after six months of continuous positive airway pressure treatment. Sleep, 2022, 45, .	1.1	19
4	The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer, 2022, 165, 124-132.	2.0	15
5	To "tell or not to tellâ€â€"exploring disclosure about medicine use by people living with sleep disorders. Journal of Integrative Medicine, 2022, , .	3.1	O
6	Cardiopulmonary coupling and serum cardiac biomarkers in obesity hypoventilation syndrome and obstructive sleep apnea with morbid obesity. Journal of Clinical Sleep Medicine, 2022, 18, 1063-1071.	2.6	0
7	Clinical predictors of working memory performance in obstructive sleep apnea patients before and during extended wakefulness. Sleep, 2022, 45, .	1.1	1
8	The Perspectives of Australian Naturopaths about Providing Health Services for People with Sleep Disorders. Behavioral Sleep Medicine, 2021, 19, 318-332.	2.1	2
9	Inspiratory Muscle Training Improves Inspiratory Muscle Strength and Functional Exercise Capacity in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Randomised Controlled Study. Heart Lung and Circulation, 2021, 30, 388-395.	0.4	14
10	Sleep EEG microstructure is associated with neurobehavioural impairment after extended wakefulness in obstructive sleep apnea. Sleep and Breathing, 2021, 25, 347-354.	1.7	26
11	Does craniofacial morphology relate to sleep apnea severity reduction following weight loss intervention? A patient-level meta-analysis. Sleep, 2021, 44, .	1.1	7
12	A pilot randomized trial comparing CPAP versus bilevel PAP spontaneous mode in the treatment of hypoventilation disorder in patients with obesity and obstructive airway disease. Journal of Clinical Sleep Medicine, 2021, , .	2.6	6
13	Development and validation of a model for diagnosis of obstructive sleep apnoea in primary care. Respirology, 2021, 26, 989-996.	2.3	3
14	Predictors of weight loss in obese patients with obstructive sleep apnea. Sleep and Breathing, 2021, , 1.	1.7	0
15	Sleep spindle activity correlates with implicit statistical learning consolidation in untreated obstructive sleep apnea patients. Sleep Medicine, 2021, 86, 126-134.	1.6	9
16	Cardiovascular disease in obesity hypoventilation syndrome $\hat{a}\in$ A review of potential mechanisms and effects of therapy. Sleep Medicine Reviews, 2021, 60, 101530.	8.5	10
17	The prevalence and characteristics of complementary medicine use by Australians living with sleep disorders – Results of a cross-sectional study. Advances in Integrative Medicine, 2020, 7, 14-22.	0.9	8
18	Melatonin for Rapid Eye Movement Sleep Behavior Disorder in Parkinson's disease: A Randomised Controlled Trial. Movement Disorders, 2020, 35, 344-349.	3.9	87

#	Article	IF	CITATIONS
19	Comparing treatment effects of a convenient vibratory positional device to CPAP in positional OSA: a crossover randomised controlled trial. Thorax, 2020, 75, 331-337.	5.6	18
20	The effect of acute morphine on sleep in male patients suffering from sleep apnea: Is there a genetic effect? An RCT Study. Journal of Sleep Research, 2020, 30, e13249.	3.2	1
21	Cannabidiol (CBD) and î" <sup>9</sup> -tetrahydrocannabinol (THC) for chronic insomnia disorder ( CANSLEEP' trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open, 2020, 10, e034421.	1.9	24
22	Prevalence of chronic kidney disease in obesity hypoventilation syndrome and obstructive sleep apnoea with severe obesity. Sleep Medicine, 2020, 74, 73-77.	1.6	2
23	Slow-frequency electroencephalography activity during wake and sleep in obesity hypoventilation syndrome. Sleep, 2019, 43, .	1.1	9
24	Benzodiazepine usage and patient preference for alternative therapies: A descriptive study. Health Science Reports, 2019, 2, e116.	1.5	6
25	Nonâ€invasive ventilation versus oxygen therapy in cystic fibrosis: A 12â€month randomized trial. Respirology, 2019, 24, 1191-1197.	2.3	15
26	Intraâ€individual stability of <scp>NREM</scp> sleep quantitative <scp>EEG</scp> measures in obstructive sleep apnea. Journal of Sleep Research, 2019, 28, e12838.	3.2	10
27	Parsing the craniofacial phenotype: effect of weight change in an obstructive sleep apnoea population. Sleep and Breathing, 2019, 23, 1291-1298.	1.7	5
28	Nocturnal hypoxaemia is associated with adverse outcomes in interstitial lung disease. Respirology, 2019, 24, 996-1004.	2.3	35
29	0397 The Experiences of Australian Naturopaths in the Clinical Management of People Living with Sleep Disorders. Sleep, 2019, 42, A161-A161.	1.1	0
30	The effect of acute morphine on obstructive sleep apnoea: a randomised double-blind placebo-controlled crossover trial. Thorax, 2019, 74, 177-184.	5.6	29
31	Benzodiazepine use risk: Understanding patient specific risk perceptions and medication beliefs. Research in Social and Administrative Pharmacy, 2019, 15, 1317-1325.	3.0	7
32	Role of venous blood gases in hypercapnic respiratory failure chronic obstructive pulmonary disease patients presenting to the emergency department. Internal Medicine Journal, 2019, 49, 834-837.	0.8	7
33	Insomnia Management in the Australian Primary Care Setting. Behavioral Sleep Medicine, 2019, 17, 19-30.	2.1	23
34	Cough sensitivity to mannitol inhalation challenge identifies subjects with chronic cough. European Respiratory Journal, 2018, 51, 1800294.	6.7	15
35	Agreement between electronic and paper Epworth Sleepiness Scale responses in obstructive sleep apnoea: secondary analysis of a randomised controlled trial undertaken in a specialised tertiary care clinic. BMJ Open, 2018, 8, e019255.	1.9	5
36	Pharmacists' perceptions and communication of risk for alertness impairing medications. Research in Social and Administrative Pharmacy, 2018, 14, 31-45.	3.0	7

3

#	Article	IF	CITATIONS
37	Integrated primary care insomnia management in Australia. Research in Social and Administrative Pharmacy, 2018, 14, 170-179.	3.0	10
38	Maintenance diets following rapid weight loss in obstructive sleep apnea: a pilot 1â€year clinical trial. Journal of Sleep Research, 2018, 27, 244-253.	3.2	11
39	Obesity Hypoventilation Syndrome: Early Detection of Nocturnal-Only Hypercapnia in an Obese Population. Journal of Clinical Sleep Medicine, 2018, 14, 1477-1484.	2.6	22
40	Does Armodafinil Improve Driving Task Performance and Weight Loss in Sleep Apnea? A Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 941-950.	5.6	14
41	Impaired Neurobehavioural Performance in Untreated Obstructive Sleep Apnea Patients Using a Novel Standardised Test Battery. Frontiers in Surgery, 2018, 5, 35.	1.4	19
42	Brain bioenergetics during resting wakefulness are related to neurobehavioral deficits in severe obstructive sleep apnea: a 31P magnetic resonance spectroscopy study. Sleep, 2018, 41, .	1.1	6
43	Physician Decision Making and Clinical Outcomes With Laboratory Polysomnography or Limited-Channel Sleep Studies for Obstructive Sleep Apnea. Annals of Internal Medicine, 2017, 166, 332.	3.9	47
44	K-complexes, spindles, and ERPs as impulse responses: unification via neural field theory. Biological Cybernetics, 2017, 111, 149-164.	1.3	9
45	Examining the ability of empirical correlations to predict subject specific <i>in vivo</i> extrathoracic aerosol deposition during tidal breathing. Aerosol Science and Technology, 2017, 51, 363-376.	3.1	20
46	Association between Sleep Disordered Breathing and Nighttime Driving Performance in Mild Cognitive Impairment. Journal of the International Neuropsychological Society, 2017, 23, 502-510.	1.8	4
47	Performance of an automated algorithm to process artefacts for quantitative EEG analysis during a simultaneous driving simulator performance task. International Journal of Psychophysiology, 2017, 121, 12-17.	1.0	6
48	Quantitative electroencephalogram measures in adult obstructive sleep apnea – Potential biomarkers of neurobehavioural functioning. Sleep Medicine Reviews, 2017, 36, 29-42.	8.5	59
49	Management of Snoring and Sleep Apnea in Australian Primary Care: The BEACH Study (2000–2014). Journal of Clinical Sleep Medicine, 2016, 12, 1167-1173.	2.6	9
50	Timing of Administration: For Commonly-Prescribed Medicines in Australia. Pharmaceutics, 2016, 8, 13.	4.5	22
51	Awareness and attitudes of final-year pharmacy students towards chronotherapy: a needs analysis. Sleep and Biological Rhythms, 2016, 14, 329-338.	1.0	2
52	The effect of device resistance and inhalation flow rate on the lung deposition of orally inhaled mannitol dry powder. International Journal of Pharmaceutics, 2016, 513, 294-301.	5.2	18
53	Chronotherapy in practice: the perspective of the community pharmacist. International Journal of Clinical Pharmacy, 2016, 38, 171-182.	2.1	10
54	Quantitative sleep EEG and polysomnographic predictors of driving simulator performance in obstructive sleep apnea. Clinical Neurophysiology, 2016, 127, 1428-1435.	1.5	55

#	Article	IF	CITATIONS
55	Education Intervention on Chronotherapy for Final-Year Pharmacy Students. Pharmacy (Basel,) Tj ETQq1 1 0.7843	14 rgBT / 1.6	Oyerlock 10
56	Consolidating innovative practice models: The case for obstructive sleep apnea services in Australian pharmacies. Research in Social and Administrative Pharmacy, 2015, 11, 412-427.	3.0	11
57	An automated algorithm to identify and reject artefacts for quantitative EEG analysis during sleep in patients with sleep-disordered breathing. Sleep and Breathing, 2015, 19, 607-615.	1.7	34
58	Diagnostic pathways for obstructive sleep apnoea in the Australian community: observations from pharmacy-based CPAP providers. Sleep and Breathing, 2015, 19, 1241-1248.	1.7	7
59	Screening for Sleep Apnoea in Mild Cognitive Impairment: The Utility of the Multivariable Apnoea Prediction Index. Sleep Disorders, 2014, 2014, 1-7.	1.4	20
60	Obstructive sleep apnoea: does one treatment not fit all?. Lancet Respiratory Medicine, the, 2014, 2, 968-970.	10.7	3
61	Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial. Thorax, 2014, 69, 274-279.	5.6	32
62	Sleep Apnea and 20-Year Follow-Up for All-Cause Mortality, Stroke, and Cancer Incidence and Mortality in the Busselton Health Study Cohort. Journal of Clinical Sleep Medicine, 2014, 10, 355-362.	2.6	374
63	Clinical services for obstructive sleep apnea patients in pharmacies: the Australian experience. International Journal of Clinical Pharmacy, 2014, 36, 460-468.	2.1	13
64	An overview of service quality of continuous positive airway pressure services in <scp>A</scp> ustralian pharmacies. Respirology, 2014, 19, 85-91.	2.3	9
65	The Role of Sleepiness, Sleep Disorders, and the Work Environment on Heavy-Vehicle Crashes in 2 Australian States. American Journal of Epidemiology, 2014, 179, 594-601.	3.4	57
66	Timing is important in medication administration: a timely review of chronotherapy research. International Journal of Clinical Pharmacy, 2013, 35, 344-358.	2.1	69
67	The effects of a single mild dose of morphine on chemoreflexes and breathing in obstructive sleep apnea. Respiratory Physiology and Neurobiology, 2013, 185, 526-532.	1.6	45
68	A new EEG biomarker of neurobehavioural impairment and sleepiness in sleep apnea patients and controls during extended wakefulness. Clinical Neurophysiology, 2013, 124, 1605-1614.	1.5	50
69	Increasing Adherence to Obstructive Sleep Apnea Treatment with a Group Social Cognitive Therapy Treatment Intervention: A Randomized Trial. Sleep, 2013, 36, 1647-1654.	1.1	70
70	The Burden of Proof Lies with the Prosecution: Is Snoring Guilty?. Sleep, 2013, 36, 615-615.	1.1	1
71	Prevalence and Utility of Positive Pneumococcal Urinary Antigen Tests in Australian Patients with Community-Acquired Pneumonia. ISRN Infectious Diseases, 2013, 2013, 1-5.	0.5	2
72	Residual sleep-disordered breathing during autotitrating continuous positive airway pressure therapy. European Respiratory Journal, 2012, 39, 1391-1397.	6.7	20

#	Article	lF	Citations
73	Snoring Is Not Associated With All-Cause Mortality, Incident Cardiovascular Disease, or Stroke in the Busselton Health Study. Sleep, 2012, 35, 1235-1240.	1.1	45
74	Treatment experience of people with obstructive sleep apnoea seeking continuous positive airways pressure device provision through community pharmacies – a role for pharmacists?. International Journal of Pharmacy Practice, 2011, 19, 318-327.	0.6	13
75	Smoking Is Not Better For You Than Sleep Apnea. Journal of Clinical Sleep Medicine, 2011, 07, 317-317.	2.6	0
76	How do pharmacists respond to complaints of acute insomnia? A simulated patient study. International Journal of Clinical Pharmacy, 2011, 33, 237-245.	2.1	44
77	The Heavy Vehicle Study: a case-control study investigating risk factors for crash in long distance heavy vehicle drivers in Australia. BMC Public Health, 2010, 10, 162.	2.9	18
78	Diagnostic accuracy of a questionnaire and simple home monitoring device in detecting obstructive sleep apnoea in a Chinese population at high cardiovascular risk. Respirology, 2010, 15, 952-960.	2.3	57
79	Comparison between a Single-Channel Nasal Airflow Device and Oximetry for the Diagnosis of Obstructive Sleep Apnea. Sleep, 2010, 33, 1106-1114.	1.1	39
80	The Utility of Single-Channel Nasal Airflow Pressure Transducer in the Diagnosis Of OSA at Home. Sleep, 2010, 33, 1097-1105.	1.1	38
81	The Role of Single-Channel Nasal Airflow Pressure Transducer in the Diagnosis of OSA in the Sleep Laboratory. Journal of Clinical Sleep Medicine, 2010, 06, 349-356.	2.6	11
82	The role of single-channel nasal airflow pressure transducer in the diagnosis of OSA in the sleep laboratory. Journal of Clinical Sleep Medicine, 2010, 6, 349-56.	2.6	7
83	Assessment of the test–retest reliability of laboratory polysomnography. Sleep and Breathing, 2009, 13, 163-167.	1.7	107
84	Is Sleep Apnea an Independent Risk Factor for Prevalent and Incident Diabetes in the Busselton Health Study?. Journal of Clinical Sleep Medicine, 2009, 05, 15-20.	2.6	145
85	Is sleep apnea an independent risk factor for prevalent and incident diabetes in the Busselton Health Study?. Journal of Clinical Sleep Medicine, 2009, 5, 15-20.	2.6	79
86	Diagnostic test evaluation of a nasal flow monitor for obstructive sleep apnea detection in sleep apnea research. Behavior Research Methods, 2008, 40, 360-366.	4.0	32
87	Comparing the neurocognitive effects of 40 h sustained wakefulness in patients with untreated OSA and healthy controls. Journal of Sleep Research, 2008, 17, 322-330.	3.2	37
88	Sleep-disordered Breathing Before and After Lung Transplantation. Journal of Heart and Lung Transplantation, 2008, 27, 540-546.	0.6	22
89	Sleep Apnea as an Independent Risk Factor for All-Cause Mortality: The Busselton Health Study. Sleep, 2008, , .	1.1	267
90	Two Randomized Placebo-Controlled Trials to Evaluate the Efficacy and Tolerability of Mirtazapine for the Treatment of Obstructive Sleep Apnea. Sleep, 2008, 31, 824-831.	1.1	188

## KEITH K H WONG

#	Article	IF	CITATIONS
91	Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep, 2008, 31, 1079-85.	1.1	554
92	Increased Adherence to CPAP With a Group Cognitive Behavioral Treatment Intervention: A Randomized Trial. Sleep, 2007, 30, 635-640.	1.1	229
93	Effect of simulated altitude during sleep on moderate-severity OSA. Respirology, 2006, 11, 62-69.	2.3	49
94	BRAIN FUNCTION IN OBSTRUCTIVE SLEEP APNEA: RESULTS FROM THE BRAIN RESOURCE INTERNATIONAL DATABASE. Journal of Integrative Neuroscience, 2006, 05, 111-121.	1.7	27
95	High-Pressure Liquid Chromatographic Quantitation of Rifampin and Its Two Major Metabolites in Urine and Serum. Clinical Infectious Diseases, 1983, 5, S433-S439.	5 <b>.</b> 8	32